Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Comment by rongoon Oct 03, 2016 11:50am

194 Views

Post# 25302311

RE:5% MB for patients MODS>9; 18% MB for other subgroups

I think he made a mistake assuming the patients who qualified but were not randomized were representative of the patients who were randomized. I am curious why some patients had more endotoxin removed than others? How do you measure that since the body is constantly producing more endotoxin? Should we administer more than 2 cartridges?

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute